Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Prostate cancer is not just a man’s concern — the use of PSA screening in transgender women

Subjects

Transgender women remain at risk of prostate cancer and warrant consideration for PSA screening. However, current PSA reference ranges and guidelines are based on data from cisgender men. As these thresholds might be inappropriate in transgender women receiving gender-affirming hormones, we recommend that these patients should undergo screening for prostate cancer at regular intervals and further evaluation for PSA >1 ng/ml or rising PSA. Furthermore patient-centred dialogues should be initiated with patients to ensure awareness of prostate cancer risk.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

References

  1. Deebel, N. A. et al. Prostate cancer in transgender women: incidence, etiopathogenesis, and management challenges. Urology 110, 166–171 (2017).

    Article  PubMed  Google Scholar 

  2. Baraban, E. et al. Prostate cancer in male-to-female transgender individuals: histopathologic findings and association with gender-affirming hormonal therapy. Am. J. Surg. Pathol. 46, 1650–1658 (2022).

    Article  PubMed  Google Scholar 

  3. Gooren, L. & Morgentaler, A. Prostate cancer incidence in orchidectomised male-to-female transsexual persons treated with oestrogens. Andrologia 46, 1156–1160 (2014).

    Article  CAS  PubMed  Google Scholar 

  4. Nik-Ahd, F. et al. Prostate cancer in transgender women in the Veterans Affairs Health System, 2000–2022. JAMA https://doi.org/10.1001/jama.2023.6028 (2023).

    Article  PubMed  Google Scholar 

  5. Di Zazzo, E., Galasso, G., Giovannelli, P., Di Donato, M. & Castoria, G. Estrogens and their receptors in prostate cancer: therapeutic implications. Front. Oncol. 8, 2 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  6. Carter, H. B. et al. Early detection of prostate cancer: AUA Guideline. J. Urol. 190, 419–426 (2013).

    Article  PubMed  PubMed Central  Google Scholar 

  7. Preston, M. A. et al. Baseline prostate-specific antigen level in midlife and aggressive prostate cancer in Black men. Eur. Urol. 75, 399–407 (2019).

    Article  CAS  PubMed  Google Scholar 

  8. Hudak, S. J., Hernandez, J. & Thompson, I. M. Role of 5 alpha-reductase inhibitors in the management of prostate cancer. Clin. Interv. Aging 1, 425–431 (2006).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Pitak-Arnnop, P., Messer-Peti, R., Tangmanee, C., Neff, A. & Meningaud, J.-P. Prostate cancer awareness among transgender women after gender-affirming surgery. Prostate 82, 1060–1067 (2022).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Farnoosh Nik-Ahd.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nik-Ahd, F., Anger, J.T., Cooperberg, M.R. et al. Prostate cancer is not just a man’s concern — the use of PSA screening in transgender women. Nat Rev Urol 20, 323–324 (2023). https://doi.org/10.1038/s41585-023-00780-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-023-00780-9

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer